Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Manny Gugliuzza who wrote (267)	3/2/1998 7:36:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

follow up from deb altman: is every thing still on target for corporate partnership by the end of this 1st quarter march? a= we expect to have at least one corporate partner by the end of march. when is phase II combination study with merck and glaxo to be completed and phase III to start? a=phase II will be completed during 1998. at this time phase III is not planned(nor required). are merck, glaxo, and bayer included in the several large pharmaceutical companies that immune is in disscusions with? a= can not discuss this. i really do not know why i asked that annual report 1st week of may. does the fda need to be proven to that the effect remune is having on the many patients that are improving in these clinical trails due to remune's action on the immune system? a=remune needs to demonstrate a statistically significant efficacy in order to receive fda approval. is the phase III scheduled to be completed by march of 1999 the trial without combination drugs? a= yes. any other questions i should have asked?? testing, testing, testing 1- 2- 3- 4 is everyone still here? back to the charts those bottom bollinger bands must be pierced by now. ar.